A regimen for low-dose aspirin?
- 6 November 1982
- Vol. 285 (6351) , 1299-1302
- https://doi.org/10.1136/bmj.285.6351.1299
Abstract
The effects of different regimens of 40 mg aspirin on platelet thromboxane A2 synthesis and vascular prostacyclin synthesis were determined in patients who were undergoing elective surgery for removal of varicose veins. Aspirin 40 mg taken at intervals of 48 hours consistently reduced platelet thromboxane A2 synthesis to a level at which it failed to support platelet aggregation and the associated release reaction. This effect lasted for at least 36 hours. In contrast, aspirin 40 mg every 72 hours did not have the same consistent effect. Both dose regimens led to a reduction in vascular prostacyclin synthesis 12 hours after the last dose, but 36 or 72 hours after the last dose prostacyclin synthesis was not reduced; thus the inhibition of prostacyclin synthesis was short lived. If the balance between platelet thromboxane A2 and vascular prostacyclin synthesis is important in thrombosis 40 mg aspirin every 48 hours may have the maximum antithrombotic effect.This publication has 21 references indexed in Scilit:
- DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESISThe Lancet, 1981
- Dissimilar effects of prostacyclin on cardiac output and forearm blood flow in healthy menClinical Physiology and Functional Imaging, 1981
- Inhibition of Prostacyclin and Platelet Thromboxane A2after Low-Dose AspirinNew England Journal of Medicine, 1981
- The differential inhibition of prostaglandin synthesis in platelets and vascular tissue in response to aspirinProstaglandins and Medicine, 1980
- ASPIRIN AND PLATELETSThe Lancet, 1980
- The Inhibitory Effect of Aspirin on Platelet and Vascular Prostaglandins in Rats cannot be Completely DissociatedBritish Journal of Haematology, 1979
- Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblastsCell, 1979
- Inhibition of platelet prostaglandin synthetase by oral aspirin.Journal of Clinical Investigation, 1978
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976